High Rates of Viral Suppression following Long-Term Entecavir Treatment of Asian

StephenW

Clin Gastroenterol Hepatol. 2012 Apr 1. [Epub ahead of print]
High Rates of Viral Suppression following Long-Term Entecavir Treatment of Asian Patients with HBeAg-Positive Chronic Hepatitis B.Pan CQ, Tong M, Kowdley KV, Hu KQ, Chang TT, Lai CL, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N.
SourceDivision of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA.

AbstractThere are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post-hoc analysis of 94 Asian, hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analog-naïve patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing Week 240, 95% (63/66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50/66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, another 40% (26/65) achieved HBeAg loss and 18% (12/65) underwent HBeAg seroconversion after 5 years of therapy with entecavir. No resistance to entecavir was detected and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.

StephenW

临床胃肠肝胆病杂志。2012年4月1。 [出处提前打印]
亚洲患者的长期恩替卡韦治疗HBeAg阳性慢性乙型肝炎的高利率抑制病毒
重庆泛塘中号，Kowdley千伏，胡克勤，张TT，赖才，尹SK，李SS，科恩ð，唐Ĥ，蔡N.
源

科肝病，西奈山医学院，纽约，纽约，美国。
摘要

有长期恩替卡韦治疗慢性乙型肝炎（CHB）的亚洲患者的影响是有限的数据。我们的表现1，事后分析94亚洲肝炎乙e抗原阳性（HBeAg阳性+），核苷（T）IDE模拟，天真的病人谁收到与恩替卡韦（最多2个多年研究教育电视-022和“5年的治疗其余在研究ETV-901）。完成周240的患者当中，有95％（63/66）乙肝病毒DNA水平<300拷贝/毫升，76％（50/66），谷丙转氨酶的正常水平。此外ETV-022期间取得的血清学反应的患者，另外40％（26/65）实现HBeAg消失和18％（12/65）接受恩替卡韦治疗5年后HBeAg的血清转换。没有恩替卡韦的耐药性检测和安全性是与以前的报告相一致。恩替卡韦的长期疗效和安全，因此，亚洲人和总人口+慢性乙型肝炎患者的HBeAg之间的可比性。